Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

Researchers find NCT analogs show antimicrobial, anticoagulant activity

Catheter-related bacteremia can be a significant cause of sickness and death for hemodialysis patients. The anticoagulant heparin is commonly used as a catheter lock solution to prevent thrombosis; however has limited antimicrobial activity.

16 Sep 2010

Momenta Pharmaceuticals receives patent for enoxaparin

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping".

14 Sep 2010

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty.

8 Sep 2010

Researchers find link between surgery duration with deep venous thrombosis risk

One of the most severe complications of brain surgery is a life-threatening blood clot in the lungs called a pulmonary embolism.But a Loyola University Health System study published in the Journal of Neurosurgery suggests that screening methods hospitals typically use to access the risk of pulmonary embolisms may fall short.

3 Sep 2010

Study finds acupuncture can control side effects of cancer treatment

Recent studies have shown that acupuncture can help control a number of symptoms and side effects such as pain, fatigue, dry mouth, nausea, and vomiting associated with a variety of cancers and their treatments.

3 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

$Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux$

Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux

Results from the FUTURA/OASIS 8 study presented today at the ESC Congress provide initial evidence that a low dose of unfractionated heparin does not reduce the incidence of bleeding or vascular complications in PCI patients treated with the anticoagulant fondaparinux. Findings showed that the rates of peri-PCI major bleeding were 1.4% in those given low dose heparin and 1.2% the standard dose.

31 Aug 2010

Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications

With both bleeding und thrombotic complications having a negative effect on PCI outcomes, increasing efforts have been made to improve PCI anticoagulation regimens. Although unfractionated heparin has been the standard anti-thrombotic agent in interventional cardiology for decades, there is still no solid evidence from large clinical trials to guide its dosing during PCI.

31 Aug 2010

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.

31 Aug 2010

$Heparin enoxaparin may provide better outcomes than unfractionated heparin$

Heparin enoxaparin may provide better outcomes than unfractionated heparin

Results from ATOLL, a phase 3 randomised trial comparing two anticoagulants in primary PCI for ST elevation MI, show that the low molecular weight heparin enoxaparin may provide better outcomes in such cases than the traditionally used unfractionated heparin.

30 Aug 2010

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin death, recurrent acute coronary syndrome or urgent revascularisation. The results of the ATOLL study were presented at the hotline session of the annual European Cardiology Congress (ESC 2010) in Stockholm, Sweden.

30 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

Pew Prescription Project announces support for new safety legislation

The Pew Prescription Project, joined by major consumer, physician and chemical manufacturer groups, today announced support for a new bill that would give the U.S. Food and Drug Administration much-needed authorities to better protect pharmaceutical supply chains. The organizations made the announcement in a joint letter to Congress and during an audio news conference with Senator Michael Bennet (D-CO), who will introduce this drug safety legislation.

4 Aug 2010

IL releases new HemosIL HIT-Ab(PF4-H) assay

Instrumentation Laboratory (IL) today announced the release of the new HemosIL HIT-Ab(PF4-H) assay as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. Delivering results in minutes, the HemosIL HIT-Ab(PF4-H) assay detects total immunoglobulin against Platelet Factor 4-Heparin complexes, the antibodies associated with the pathology of HIT.

4 Aug 2010

ProtAffin signs manufacturing contract with CMC Biologics for COPD drug PA401

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today announced it has signed a manufacturing contract with CMC Biologics' Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications.

27 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

Cardiva Medical, Advanced Vascular Dynamics sign agreement to distribute hemostasis products

Cardiva Medical, Inc. announced today that it has signed an agreement with Advanced Vascular Dynamics to distribute several products used for postcatheterization femoral and radial artery hemostasis in the U.S.

27 Jul 2010

First generic version of Lovenox receives FDA approval for DVT

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis, a potentially deadly blood clotting condition.

23 Jul 2010

Heparin News and Research

Further Reading

Researchers find NCT analogs show antimicrobial, anticoagulant activity

Momenta Pharmaceuticals receives patent for enoxaparin

Late breaking clinical trials in interventional cardiovascular medicine to be presented at TCT 2010

Researchers find link between surgery duration with deep venous thrombosis risk

Study finds acupuncture can control side effects of cancer treatment

XARELTO achieves net clinical benefit in treatment of patients with DVT

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

Unfractionated heparin standard dose may be optimal treatment strategy in PCI patients on fondaparinux

Reduced heparin dose lowers bleeding risk after PCI without increasing risk of ischaemic complications

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Heparin enoxaparin may provide better outcomes than unfractionated heparin

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

Pew Prescription Project announces support for new safety legislation

IL releases new HemosIL HIT-Ab(PF4-H) assay

ProtAffin signs manufacturing contract with CMC Biologics for COPD drug PA401

Abbot's innovative solutions to be highlighted at AACC

Cardiva Medical, Advanced Vascular Dynamics sign agreement to distribute hemostasis products

First generic version of Lovenox receives FDA approval for DVT

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News